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Abstract
The liver stage of Plasmodium’s life cycle is the first, obligatory step in malaria infection. Decreasing the hepatic burden of
Plasmodium infection decreases the severity of disease and constitutes a promising strategy for malaria prophylaxis. The
efficacy of the gamma-secretase and signal peptide peptidase inhibitor LY411,575 in targeting Plasmodium liver stages was
evaluated both in human hepatoma cell lines and in mouse primary hepatocytes. LY411,575 was found to prevent
Plasmodium’s normal development in the liver, with an IC50 of approximately 80 nM, without affecting hepatocyte invasion
by the parasite. In vivo results with a rodent model of malaria showed that LY411,575 decreases the parasite load in the liver
and increases by 55% the resistance of mice to cerebral malaria, one of the most severe malaria-associated syndromes. Our
data show that LY411,575 does not exert its effect via the Notch signaling pathway suggesting that it may interfere with
Plasmodium development through an inhibition of the parasite’s signal peptide peptidase. We therefore propose that
selective signal peptide peptidase inhibitors could be potentially used for preventive treatment of malaria in humans.
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Introduction
Malaria is a devastating parasitic disease accounting for 1 to 2
million deaths per year, mostly among children in Sub-Saharan
Africa, Asia, Central and South America. During the last two
decades, the incidence of malaria has been increasing, largely due
to an emergence of parasite variants resistant to the two most
widely used drugs, chloroquine and sulphadoxine/pyrimethamine.
This fact, taken together with the largely unsuccessful attempts for
antimalarial vaccination, makes the development of new drugs
against this disease critically important [1].
Malaria is caused by protozoan parasites from the Plasmodium
genus. Plasmodium sporozoites are transmitted to the mammalian
host by a mosquito bite and transported with the blood stream to
the liver. Once in the liver, the parasites cross the sinusoidal wall,
presumably through Kupffer cells, and migrate through several
hepatocytes before infecting a final cell, which they enter with
formation of a parasitophorous vacuole [2–4]. Within the vacuole,
the sporozoites develop and produce thousands of merozoites,
which are released into the bloodstream and infect erythrocytes
[5,6]. The liver stage of the disease is clinically silent while all
pathological manifestations develop during the blood stage [7,8].
All currently used antimalarial agents, with the exception of
primaquine, target blood stage parasites. Drugs against liver stage
malaria would block the development of the parasites and prevent
pathology. It is therefore crucial to develop novel agents against
this stage of infection.
One of the emerging strategies for treatment of malaria is the
use of enzymatic inhibitors. A number of enzymes essential for
parasite metabolism have been recognized as attractive targets for
novel drug development. Inhibitors of the plasmepsin family of
aspartyl proteases are already established as potential agents
against blood stage malaria through extensive data generated in
cell culture and mouse models [9–11]. Inhibitors targeting the
falcipains, a family of P. falciparum cysteine proteases involved in
hemoglobin degradation and erythrocyte invasion, have demon-
strated potent antimalarial effects and their testing and optimiza-
tion as antimalarials is under way (reviewed in [12]). Additionally,
HIV protease inhibitors already in clinical use were also shown to
inhibit growth of P. falciparum in culture P. berghei in mice [13,14].
Here we show that the gamma-secretase and signal peptide
peptidase (SPP) inhibitor LY411,575, but not the selective gamma-
secretase inhibitor (GSI) DAPT, impairs development of P. berghei
in vitro in hepatoma cells as well as in vivo in mouse liver. These data
indicate that Plasmodium SPP is a potential therapeutic target for
malaria, and provide rationale for development of selective
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scaffold as novel treatments for malaria.
Results
LY411,575 reduces the load of P. berghei ANKA in hepatic
cells in a dose-dependent manner
In order to measure the influence of LY411,575 on P. berghei
development monolayers of human hepatoma Huh7 cells cultured
in 24-well tissue culture plates, were treated with concentrations of
the inhibitor ranging from 100 to 750 nM. Control cells were
incubated with medium contaning 0.01% DMSO. Cells were
infected with P. berghei ANKA sporozoites immediately after
addition of the inhibitor. Twenty-four h after infection cells were
either fixed with PFA and stained for P. berghei HSP70 or lysed in
RLT buffer (Qiagen RNeasy Micro Kit) and used for RNA
isolation. Infection was quantified by counting the number of
infected cells (exo-erythrocytic forms, EEFs) per well, by qRT-
PCR or by FACS. The inhibitor blocked the development of the
parasites in a dose-dependent manner. Concentrations as low as
100 nM reduced the number of EEF-containing cells, as detected
and counted by microscopy, by 45%. At concentrations above
500 nM no EEFs could be detected by microscopy (Fig. 1A). The
IC50 of LY411,575 calculated on the basis on infection
measurement by qRT-PCR (Fig. 1B) was ,80 nM.
The inhibitor did not only reduce the number of EEFs but also
their size (Fig. 1 C,D,E). After 48 h treatment with LY411,575 the
average size of the EEFs in cells treated with the drug was 5 to 6
times smaller than in control cells (Fig 1C,D). Furthermore, cells
treated with 250 nM LY411,575 and analyzed 30 h after
sporozoite addition by FACS showed a greatly reduced average
GFP fluorescence intensity per EEF, compared to controls (Fig 1E).
Since GFP in these parasites is expressed under the control of the
P. berghei house keeping gene (EF1a) promoter region, the results
are consistent with the presence of smaller and less developed
EEFs in the presence of LY411,575. In addition, the infection load
in mouse primary hepatocytes treated with the same amount of
LY411,575 and analyzed 48 h after sporozoite addition by qRT-
PCR was ,80% lower than that of control cells (Fig 1F), showing
that the compound inhibits infection ex vivo as well as in vitro.
LY411,575 acts on the early developmental stages of the
parasites but does not affect their entry in cells
Hepatocyte infection by Plasmodium may be conceptually
divided into two consecutive steps: hepatocyte invasion and
intracellular parasite development. In our in vitro infection model,
over 95% of the infective sporozoites have completed the
migration and invasion steps at 2 h after addition to the cells
[15]. The overall effect of LY411,575 on infection observed above
could be due to an interference of the drug with invasion of the
host cells by the sporozoites, with the subsequent parasite
development or with both these processes. The experimental
design used above could not allow us to distinguish between these
possibilities. To determine whether LY411,575 was affecting
sporozoite invasion, we treated cells with 100 to 500 nM of
LY411,575 1 h prior to and during the initial 2 h of infection with
GFP-expressing P. berghei sporozoites. Cells were then collected 2 h
after sporozoite addition and the infection level was analyzed by
FACS. The percentage of infected cells in the treated samples was
similar to that found in control cells, indicating that the compound
does not interfere with the invasion process (Fig. 2A). Thus, the
LY411,575-mediated decrease on infection depicted in Fig. 1
results solely from an interference of the drug with the intracellular
development of the parasite, an effect that is clearly visible when
infection was monitored 30 or 48 h after sporozoite addition (see
Fig. 1 C,D,E). To test the influence of LY411,575 on the different
stages of development of P. berghei ANKA Huh7 cells were treated
with LY411,575 for periods of 6 h and infection level was
measured by microscopy 24 h after sporozoite addition (Fig. 2B).
The observed decrease in the number of EEFs in the samples
treated during the initial period of infection clearly suggests that
LY411,575 affects the P. berghei growth during the early
developmental stages.
The effect of LY411,575 on Plasmodium development is
not due to an interference with the cellular Notch
signaling pathway
The effect of LY411,575 on parasite development could be due
to inhibition of the function of one or more of its known targets.
Well-established targets of this inhibitor are the cellular gamma-
secretase complex [16,17] (and, subsequently, the downstream
Notch signaling pathway) and the cellular signal peptide peptidase
(SPP) [18]. Importantly, LY411,575 was recently shown to
effectively block the activity of the P. falciparum SPP homologue
in in vitro activity assays [19]. Furthermore, our analysis of the
Plasmodium SPP homologous sequences listed in PlasmoDB showed
that all Plasmodium species, including P. berghei, contain a single SPP
homologue.
In order to distinguish whether the observed effect of
LY411,575 was exerted on the host cell or on the parasite, target
cells were treated during the time periods shown on Fig. 3A. As
can be seen on this figure, pretreatment of the cells with
LY411,575 was not sufficient to block parasite development.
The effect of the inhibitor was only detected when the compound
was present in the culture medium during the process of
development. We therefore concluded that the effect of the
inhibitor is most likely on the parasite itself and not due to
influence on cellular signaling through gamma-secretase or on
cellular SPP.
Additional evidence for the independence of the LY411,575
effect on Plasmodium development from the cellular Notch signaling
pathway was obtained by experiments with the gamma-secretase
inhibitor DAPT. DAPT was previously shown to specifically block
gamma-secretase but not SPP [18]. It is well established that 1 mM
DAPT is sufficient to completely block the activity of the gamma-
secretase in cellular assays [20]. Incubation of Huh7 cells with
10 mM DAPT for various periods did not affect the number of
cells containing EEFs detectable by microscopy (Fig. 3B). Ten mM
DAPT also had no effect on infection of primary hepatocytes by P.
berghei ANKA measured by qRT-PCR (Fig. 3C). When cells
treated with DAPT were analyzed by FACS at 2 h (Fig. 3D) and
30 h (Fig. 3E) after addition of GFP-expressing sporozoites, no
significant differences were observed in the percentage of GFP-
positive cells or in GFP intensity, respectively, relative to controls.
We therefore concluded that the Plasmodium growth inhibition
caused by LY411,575 is not due to inhibtion of host gamma-
secretase activity.
LY411,575 reduces development of P. berghei ANKA in
mouse livers
In order to analyze the in vivo effect of LY411,575, C57BL/6
mice were treated by intraperitoneal (i.p.) injection of the inhibitor
in doses ranging from 1 to 10 mg/kg body weight and infected
with 20000 P. berghei ANKA sporozoites. The mice received two
injections of 100 ml, at 2 h before infection and 24 h later. Control
animals were treated with an equivalent amount of DMSO. Forty
h after infection the animals were sacrificed, their livers were
Plasmodium SPP Inhibition
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qRT-PCR (Fig. 4A). The results clearly show that treatment with
LY411,575 leads to a dose-dependent reduction in liver parasite
load. We therefore hypothesized that the reduced Plasmodium liver
load in LY411,575-treated mice might have a positive influence on
the further development of disease in these animals. To test this
hypothesis, C57BL/6 mice were treated with 10 mg/kg body
weight of the inhibitor, infected with 1000 P. berghei ANKA
Figure 1. LY411,575 decreases infection of hepatic cells by P. berghei ANKA sporozoites. (A, B) Dose-dependent effect of LY411,575 on
infection of Huh7 cells, measured by immunofluorescence microscopy (A) or qRT-PCR (B). Control cells were treated with an amount of DMSO
equivalent to that of the highest drug concentration and infection was measured 24 h after addition of 20000 P. berghei ANKA sporozoites.
Experiments were conducted in triplicates. Results are plotted as percentages of the mean value of the control samples (A) (*: p,0.02, **: p,0.01, ***:
p,0.001) or as parasite-specific 18S rRNA as measured by qRT PCR (B) (Black circles represent the mean of P. berghei ANKA18S rRNA expression in
each condition, n=3). (C) Representative images of EEFs in Huh7 cells treated for 48 h with 100 nM LY411,575 and solvent-treated control cells. EEFs
were stained for P. berghei HSP70 (green) and nuclei were stained with DAPI (blue). (D) Size distribution of EEFs in Huh7 cells treated for 48 h with
100 nM LY411,575 and solvent-treated control cells. Pictures of 50 EEFs were taken from each coverslip and the size of the EEFs was measured using
the ImageJ software. (E) Representative lines of GFP intensity of Huh7 cells treated with 250 nM LY411,575 and solvent-treated control cells 30 h after
addition of 20000 GFP-expressing P. berghei ANKA sporozoites, analyzed by FACS. (F) Effect of LY411,575 on infection of mouse primary hepatocytes,
measured by qRT-PCR 48 h after addition of 25000 P. berghei ANKA sporozoites. Control cells were treated with an equivalent amount of DMSO.
Experiments were conducted in triplicates. Results are plotted as percentages of the mean value of the control samples. *: p,0.02.
doi:10.1371/journal.pone.0005078.g001
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received two injections of LY411,575, as previously described, and
were monitored daily for symptoms of CM and death. Blood
parasitemia (percentage of infected red blood cells) was measured
from day 5 after infection by FACS. LY411,575-treated mice
developed significantly lower levels of blood parasitemia when
compared to control animals, very evident during the days before
development of severe symptoms (Fig. 4B). The drug treatment
also influenced significantly the incidence of CM, with
LY411,575-treated mice displaying 55% increase in CM survival
when compared to control animals (Fig. 4C). To determine
whether the observed effect on CM was due to direct influence of
LY411,575 on development of P. berghei ANKA blood stages or
instead just due to the decreased caused in liver infection, C57BL/
6 mice were treated with 10 mg/kg body weight of the inhibitor,
infected with 5610
4 P. berghei-infected red blood cells (iRBCs) and
disease progression was followed. The animals received three i.p.
injections of 50 ml, at 2 h before infection with iRBC and at days 2
and day 4 after infection. Control animals were treated with the
equivalent amounts of DMSO. Mice were monitored daily for
symptoms of CM and death. Blood parasitemia was measured
from day 3 after infection by FACS. Treated mice displayed
slightly lower parasitemia levels (Fig. 4D). This small difference
was not sufficient to influence the development of CM with both
groups of mice showing similar survival curves (Fig. 4E).
Altogether these data suggest that LY411,575 alters the course
of the blood stage of infection by reducing significantly Plasmodium
liver stage development.
Discussion
Despite the attempts for its eradication, malaria is still among
the most deadly diseases in the world. During the last 20 to 30
years Plasmodium parasites, the causative agent of the disease, have
developed resistance to the major groups of antimalarial drugs
currently in use. Therefore new antimalarials with novel
mechanisms of action are urgently needed.
A few families of Plasmodium proteases have emerged during the
last couple of years as new potential targets for treatment of
malaria, the best characterized among these being the plasmepsins
and falcipains. Different classes of inhibitors of these proteases
have been developed that show promising results in both
Plasmodium culture and mouse models [9–12]. HIV protease
inhibitors currently in clinical use also show antimalarial activity
[13,14].
Here we report that LY411,575 reduces development of P.
berghei ANKA in human hepatoma cells, primary hepatocytes and
mouse livers. Though developed as a potent GSI, LY411,575 also
blocks the activity of all human SPP homologues and P. falciparum
SPP with reasonable potency [18,19]. LY411575 is not unique and
one of many compounds developed as potential therapeutic agents
for the treatment of Alzheimer’s disease (AD) that appear capable
of blocking GSI and SPP activity. Indeed, at least two GSIs are
currently being tested as in the clinic [21,22].
SPP, the prototypic member of the human SPP family of
aspartyl proteases catalyzes intramembrane proteolysis of some
signal peptides after they have been cleaved from a preprotein and
also of several viral preproteins [23–25]. SPPL2a and SPPL2b
were recently shown to promote intramembrane cleavage of TNF-
alpha in activated dendritic cells [26]. Little is known about the
functions of SPP homologues in other organisms but there is
increasing suggestive evidence that these molecules play critical
role in development in a number of species. Caenorhabditis elegans
deficient for the SPP homologue ce-imp2 shows a very severe
developmental phenotype [27]. In Drosophila, deficiency for
CG11840, one of the two SPP homologues present in this
organism, leads to death during larval stage due to problems
Figure 2. LY411,575 affects development, but not invasion, of
P. berghei parasites. (A) Effect of the incubation of Huh7 cells with
various amounts of LY411,575 on the percentage of GFP-positive cells
collected 2 h after addition of 20000 GFP-expressing P. berghei ANKA
sporozoites and analysed by FACS. Control cells were treated with an
amount of DMSO equivalent to that of the highest drug concentration.
Experiments were conducted in triplicates. Results are plotted as
percentages of the mean value of the control samples. (B) Effect of the
incubation of Huh7 cells with 100 nM LY411,575 during various 6 hour
intervals and for 24 h. Infection was measured by immunofluorescence
microscopy 24 h after addition of 20000 P. berghei ANKA sporozoites.
Control cells were treated with equivalent amounts of DMSO.
Experiments were conducted in triplicates. Results are plotted as
percentages of the mean value of the control samples. *: p,0.02,
**: p,0.01, ***: p,0.001.
doi:10.1371/journal.pone.0005078.g002
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either SPP or SPPL3 homologues results in cell death in the
central nervous system; knock down of SPPL2b in the same
organism leads to caudal vein enlargement [29].
We hypothesized that the Plasmodium SPP homologue could be
required for development of the parasite in the host cell and
inhibitors of this protease could block the developmental process.
Consistent with previous studies [19] analysis of the SPP
homologous sequences present in PlasmoDB showed that a single
SPP-like protein is present in each of the Plasmodium species
including the rodent parasite P. berghei (acc. numbers PF14_0543,
PB001192.00.0 and PY06507 for P. falciparum, P. berghei and P.
yoelii, respectively). Moreover, relative expression profiles show
that P. yoelii and P. berghei SPP is equally expressed in both in liver
and blood stages (http://plasmodb.org/plasmo/ and our own
data not shown, respectively). As selective SPP inhibitors have not
been developed for in vivo use, we tested our hypothesis using
LY411,575, a compound developed as a gamma-secretase
inhibitor that also inhibits SPPs including P. falciparum SPP [19].
We could clearly show that LY411,575 efficiently blocked the
development of P. berghei ANKA in hepatic cells in a dose-
dependent manner with an IC50 of ,80 nM (Fig. 1). Our detailed
analysis of the LY411,575 effect on Plasmodium showed that the
inhibitor blocked the early stages of parasite development (Fig. 2B).
The effect of LY411,575 on Plasmodium development could be due
to inhibition of SPP activity but also potentially to an interference
with cellular host Notch signaling as a result of inhibition of the
cellular gamma-secretase complex. We excluded the latter
Figure 3. Plasmodium growth inhibition is not due to an interference with the cellular Notch signaling pathway. (A) Effect of the
incubation of Huh7 cells with 100 nM LY411,575 for different periods relative to sporozoite addition. Infection was measured by immunofluorescence
microscopy 48 h after addition of 20000 P. berghei ANKA sporozoites. Control cells were treated with an equivalent amount of DMSO. Experiments
were conducted in triplicates. Results are plotted as percentages of the mean value of the control samples. *: p,0.05. (B, C) Effect of 10 mM DAPT on
infection of Huh7 cells, measured by immunofluorescence microscopy (B) or qRT-PCR (C) 30 h after addition of 20000 P. berghei ANKA sporozoites.
Control cells were treated with an equivalent amount of DMSO. Experiments were conducted in triplicates. Results are plotted as percentages of the
mean value of the control samples. (D) Effect of the incubation of Huh7 cells with 10 mM DAPT on the percentage of GFP-positive cells collected 2 h
after addition of 20000 GFP-expressing P. berghei ANKA sporozoites and analysed by FACS. Control cells were treated with an amount of DMSO
equivalent to that of the highest drug concentration. Experiments were conducted in triplicates. Results are plotted as percentages of the mean value
of the control samples. (E) Representative lines of GFP intensity of Huh7 cells treated with 10 mM DAPT and solvent-treated control cells 30 h after
addition of 20000 GFP-expressing P. berghei ANKA sporozoites and analysed by FACS.
doi:10.1371/journal.pone.0005078.g003
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inhibitor DAPT, which had no effect on P. berghei ANKA
development (Fig. 3B, C, D, E). Furthermore, pretreatment of
cells with LY411,575 did not affect the development of the
parasites (Fig. 3A). The drug inhibited development only when
present throughout the process. These data seem to suggest that
the effect of LY411,575 on Plasmodium development is probably
due to an effect on the parasite itself and not on the host cell.
We could not detect any effect of LY411,575 on invasion of
hepatocytes by P. berghei sporozoites. This seems surprising
considering the recently published results from Li et al. [30],
which show that a SPP antibody generated by them blocks RBC
Figure 4. LY411,575 decreases liver P. berghei infection in vivo and increases CM survival. (A) Dose-dependent effect of LY411,575 on liver
parasite load, measured by qRT-PCR. Control mice were treated with an equivalent amount of DMSO and infection was measured on livers collected
40 h after injection of 20000 P. berghei ANKA sporozoites (n=12 for each group). **: p,0.01, ***: p,0.001. (B) Effect of i.p. injection of 10 mg/kg
body weight LY411,575 on blood parasitemia of mice infected with 1000 P. berghei ANKA sporozoites. Control mice were treated with an equivalent
amount of DMSO and mice were monitored daily for parasite levels in the blood and disease symptoms. (n=13 for each group). Parasitemias on each
assessed day are significantly different between the two experimental groups (p,0.001). (C) Survival curves of mice treated by i.p. injection of 10 mg/
kg body weight LY411,575 and solvent-treated, control mice, infected with 1000 P. berghei ANKA sporozoites. The shaded area represents the time-
window for death with CM symptoms. The two survival curves are significantly different (p,0.01). (D) Effect of i.p. injection of 10 mg/kg body weight
LY411,575 on blood parasitemia of C57BL/6 mice infected with 50000 iRBC. Control mice were treated with an equivalent amount of DMSO and mice
(n=15 for each group) were monitored daily for parasite levels in the blood and disease symptoms. Parasitemias were not found to be significantly
different: p=0,5375 (day 4); p=0,0345 (day 5); p=0,03065 (day 6); p=0,1446 (day 7). (E) Survival curves of mice treated by i.p. injection of 10 mg/kg
body weight LY411,575 and solvent-treated, control mice, infected with 50000 iRBC sporozoites. The shaded area represents the time-window for
death with CM symptoms. The two survival curves are not significantly different (p=0.4474).
doi:10.1371/journal.pone.0005078.g004
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results are difficult to compare to that study because of the
differences in the systems used. Nevertheless, we can state that
doses of LY411,575 sufficient to partially or completely block P.
berghei development have no effect on invasion of hepatocytes by
the parasite. At the current stage of this study we cannot yet prove
that SPP is the only Plasmodium target responsible for the observed
LY411,575 effect. It is possible that the mechanism underlying the
effect of LY411,575 on parasite development is complex and
involves inhibition of more than one aspartyl protease. Further
experiments will be needed to clarify this issue.
Notably, LY411,575 also showed promising results against
Plasmodium liver stage development in mice treated with this
compound. LY411,575-treated C57BL/6 mice displayed a
decrease in Plasmodium liver load, which later manifested in lower
blood parasitemia levels. In addition, the drug treatment
significantly influenced the development of CM, with a 55%
higher mortality in the control group of animals compared to the
LY411,575-treated ones. The LY411,575 treatment scheme used
in this study provided only partial protection of mice against P.
berghei infection. Nevertheless, because the effect of the drug is
clearly dose-dependent in both cells and mice, we expect that
higher doses or longer treatment would lead to even greater
reduction in liver load and parasitemia and possibly to destruction
of all parasites by the drug in the liver. Notably, even such partial
decrease of liver load and blood parasitemia led to a significant
reduction of incidence of development of severe symptoms (CM) in
the treated group of animals. The effect of LY411,575 on the
development of P. berghei blood stages was much less pronounced.
However, the relatively small influence of LY411,575 on P. berghei
blood stages does not diminish the importance of our results.
Indeed, this may only reflect the availability of the drug in the liver
versus in circulation after i.p. administration of this specific dosage.
Nevertheless, we can conclude that LY411,575 is a potent
inhibitor of development of P. berghei in the liver.
For nearly a decade there has been a substantive effort to
develop GSIs which would reduce the production of the amyloid
b peptide that accumulates in the AD patient’s brain [31,32].
Although toxicity (largely due to inhibition of Notch signaling)
has constituted an obstacle to the clinical development of GSIs
for AD, one compound remains in a phase III human trial for
AD, and other compounds are being tested as anti-cancer agents.
In the latter case, the rationale is that several cancers have been
shown to be dependent on Notch signaling. Thus, a large array
of LY411,575-related and other non structurally related GSIs
already exists, many of which also inhibit SPP. A very promising
approach to the development novel anti-malarial agents would
be to leverage the GSI drug-discovery to find compounds that
are drug-like and inhibit SPP selectively or even more
preferentially Plasmodium SPP. Indeed, the fact that LY411,575
inhibits both SPP and GS limits the current study in terms of
efficacy. Higher doses, which might be more effective against
blood-stages, are not well tolerated due to GS toxicity related to
the GSI activity.
Materials and Methods
Mice, cells and parasites
Male C57BL/6 mice were bred and housed in the specific
pathogen free facilities of the Instituto Gulbenkian de Cie ˆncia
(IGC) according to the guidelines of the Animal Care Committee
of the IGC. All mice used were 6 to 8 weeks old.
Human hepatoma Huh7 cells (ATCC CCL-185) were cultured
in RPMI medium supplemented with 10% FCS, 1 mM glutamine,
1% non-essential aminoacids, 1% penicillin/streptomycin, 10 mM
Hepes buffer.
Green fluorescent protein (GFP)-expressing P. berghei ANKA
(parasite line 259cl2, which shows similar virulence to wild-type P.
berghei) [33] sporozoites were obtained from dissection of infected
Anopheles stephensi mosquito salivary glands at day 21–25 post-
infection, which were produced and maintained at IMM insectary.
Isolation of murine primary hepatocytes
Mouse primary hepatocytes were isolated from C57BL/6 mice
as previously described [34]. Briefly, cells were obtained by
perfusion of mouse liver lobules with liver perfusion and liver
digest medium (Gibco) at 37uC. Hepatocytes were then purified
using 1.12 g/ml, 1.08 g/ml and 1.06 g/ml Percoll gradients. Cells
were cultured in William’s E medium (Gibco) containing 4% FCS,
1% penicillin/streptomycin in 24-well plates coated with 0.2%
Gelatin in PBS.
LY411,575 and DAPT treatment and infection in vitro
LY411,575 was synthesized as previously described [35]. The
compound was reconstituted in DMSO to obtain a 10 mM stock
solution. DAPT (N-[N-(3,5-Difluorophenacetyl-L-alanyl)]-S-phe-
nylglycine t-Butyl Ester; gamma-secretase inhibitor IX) was
purchased from Calbiochem (Darmstadt, Germany) as a 25 mM
solution in DMSO.
Huh7 human hepatoma cells were treated with LY411,575 or
DAPT diluted in culture medium as described in the text. Control
cells were incubated with medium containing 0.01% or 0.04%
DMSO, respectively. Twenty thousand P. berghei ANKA sporozo-
ites were added to monolayers of 1.5610
5 Huh7 cells cultured on
glass coverslips or directly in 24-well tissue culture plates and
centrifuged for 5 min at 3000 rpm. Cells used for immunofluo-
rescence staining were fixed 24 or 48 h after infection and stained
for P. berghei HSP70. Infection was quantified by counting the
number of infected cells (exoerythrocytic forms, EEFs) per
coverslip. Huh 7 cells and primary hepatocytes used for qRT-
PCR were lysed in RLT buffer (Qiagen RNeasy Micro Kit) at 24
and 48 h after infection, respectively, and processed according to
manufacturer’s guidelines. Huh7 cells used for fluorescence
activated cell sorting (FACS) analysis were collected at 2 and
30 h after sporozoite infection.
LY411,575 treatment and infection in vivo
C57BL/6 mice were injected intraperitoneally (i.p.) with 1 to
10 mg/kg body weight (average body weight 20 mg) LY411,575
in 100 ml DMSO. Control animals were treated with the same
amount of DMSO. All mice received two injections, the first one
2 h before infection with P. berghei ANKA sporozoites and the
second one 24 h later. Mice were infected by intravenous (i.v.)
injection of 20000 (for parasite liver load measurement) or 1000
(for survival assessment) P. berghei ANKA sporozoites. Parasite load
in the liver was measured 40 h after infection by qRT PCR.
Mice monitored for survival after infected blood (iRBC)
challenge were injected i.p. with 10 mg/kg body weight
LY411,575 in 50 ml DMSO. Control animals were treated with
the same amount of DMSO. All mice received three injections, the
first one 2 h before infection with iRBC and the second and third
ones at day 2 and day 4 after infection, respectively. Mice were
infected by intraperitoneal injection of 50000 iRBC.
During survival experiments, mice were monitored every day
for disease symptoms and time of death. Parasitemias (percentage
of infected red blood cells) were measured daily by Flow
Cytometry on FACSCalibur.
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Huh7 cells were fixed with 4% paraformaldehyde (PFA) in PBS
for 20 min and incubated in blocking buffer (3% BSA, 10% FCS,
100 mM glycine, 0.1% saponin in PBS) for 1 h followed by
incubation with monoclonal antibody 2E6 against P. berghei HSP70
[36] diluted in the same buffer. Cells were then washed with 0.1%
saponin in PBS and incubated with a secondary antibody diluted
in blocking buffer (Anti-Mouse Alexa488, Molecular Probes) for
30 min. Nuclei were stained with DAPI. Images were acquired
with a Leica DM5000B fluorescence microscope and processed
using Adobe Photoshop.
Infection quantification by qRT-PCR
For infection determination in vivo or ex vivo, total RNA was
isolated from livers or primary hepatocytes using Qiagen’s RNeasy
Mini or Micro kits, respectively, following the manufacturer’s
instructions. The assessment of liver parasite load in vivo, was
performed according to the method developed for P. yoelii
infections [37]. Livers were collected and homogenized in
denaturing solution (4 M guanidine thiocyanate, 25 mM sodium
citrate pH 7, 0.5% sarcosyl and 0.7% b-Mercaptoethanol in
DEPC-treated water) 40 h after sporozoite injection. Total RNA
was extracted using Qiagen’s RNeasy Mini kit. RNA for infection
measurements was converted into cDNA using Transcriptor First
Strand cDNA Synthesis kit from Roche. The qRT-PCR reactions
used Applied Biosystems’ Power SYBR Green PCR Master Mix
and were performed on an ABI Prism 7000 system (Applied
Biosystems). Amplification reactions were carried out in a
total reaction volume of 25 ml, containing 0.8 pmol/mlo r
0.16 pmol/ml of PbA 18 S- or mouse Hypoxanthine Guanine
Phosphoribosyltransferase (HPRT) specific primers, respectively.
Relative amount of PbA mRNA was normalized against the
HPRT level in each sample. PbA 18 S- and mouse HPRT-specific
primer sequences were 59- AAG CAT TAA ATA AAG CGA
ATA CAT CCT TAC - 39 and 59 - GGA GAT TGG TTT
TGA CGT TTA TGT G - 39and 59 - TGC TCG AGA TGT
GAT GAA GG - 39 and 59 - TCC CCT GTT GAC TGG TCA
TT - 39, respectively.
Fluorescence Activated Cell Sorting (FACS) analysis
FACS analysis was performed to determine the percentage of
parasite-containing cells at 2 and 30 h after sporozoite addition as
described in [15]. Briefly, cells were washed with PBS, detached by
trypsin treatment and collected in 400 ul 10% FCS in PBS at the
selected time points after sporozoite addition. Cells were then
centrifuged at 0.1 rcf for 3 min at 4uC, resuspended in 150 ul 2%
FCS in PBS and analyzed on a Becton Dickinson FACScalibur.
Data acquisition and analysis were carried out using CELLQuest
(version 3.2.1fl1, Becton Dickinson) and FlowJo (version 6.3.4,
FlowJo) software.
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